C16 Biosciences vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
C16 Biosciences produces Palmless, a biofermentation-derived alternative to palm oil targeting the beauty, personal care, and food industries; raised $20M Series A led by Breakthrough Energy Ventures;
About
C16 Biosciences is a biotechnology company founded in 2017 by David Heller, Irina Gerry, and Harry McNamara and headquartered in New York City. The company developed a proprietary biomanufacturing platform that uses engineered yeast fermentation to produce Palmless — a sustainable, palm oil-equivalent ingredient designed for beauty, personal care, and food applications. Palm oil is one of the most widely used commodity oils in the world, but its production is responsible for massive tropical deforestation, habitat destruction, and biodiversity loss, particularly in Indonesia and Malaysia. C16's fermentation approach produces oils with the same functional performance as palm oil — high saturation, solid at room temperature, neutral flavor — without any agricultural land conversion.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.